D. Boral Capital Reaffirms “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $2.00 target price on the stock. D. Boral Capital’s price objective points to a potential upside of 284.47% from the […]
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $2.00 target price on the stock. D. Boral Capital’s price objective points to a potential upside of 284.47% from the […]
